Inhibition of osteoporosis by the &agr;v&bgr;3 integrin antagonist of rhodostomin variants

[1]  W. Fu,et al.  Upregulation of heme oxygenase‐1 inhibits the maturation and mineralization of osteoblasts , 2009, Journal of cellular physiology.

[2]  W. Fu,et al.  Regulation of the maturation of osteoblasts and osteoclastogenesis by glutamate. , 2008, European journal of pharmacology.

[3]  W. Fu,et al.  PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. , 2007, Bone.

[4]  S. Teitelbaum,et al.  Critical Role of β3 Integrin in Experimental Postmenopausal Osteoporosis , 2005 .

[5]  R. Recker,et al.  Effect of L-000845704, an αVβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women , 2005 .

[6]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[7]  L. Chou,et al.  Expression in Pichia pastoris and characterization by circular dichroism and NMR of rhodostomin , 2001, Proteins.

[8]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[9]  R. Hynes,et al.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.

[10]  G. Rodan,et al.  Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. , 1998, Endocrinology.

[11]  M A Horton,et al.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.

[12]  V. Garsky,et al.  Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. , 1993, Endocrinology.

[13]  R. Dodds,et al.  Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. , 1992, Journal of cell science.

[14]  M. Horton,et al.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. , 1991, Experimental cell research.

[15]  M. Horton,et al.  The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor , 1989, The Journal of cell biology.

[16]  M. Horton,et al.  Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro. , 1986, Bone and mineral.

[17]  J. Kanis.  Diagnosis of osteoporosis , 2010, Osteoporosis International.

[18]  S. Rodan,et al.  Involvement of alpha(v)beta3 integrins in osteoclast function. , 2007, Journal of bone and mineral metabolism.

[19]  R. Recker,et al.  Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. , 2005, The Journal of clinical endocrinology and metabolism.